Exploring the New Anticoagulants- Pharmacist


  Credits  1.5

This product is currently out of stock and unavailable.

Anticoagulants are primarily used to prevent or treat thromboembolic events in patients with conditions including deep-vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), acute coronary syndrome (ACS), heart or aortic valve replacement, and other hypercoagulable clotting disorders. This issue includes a brief review of the anticoagulants developed over the last 50 years including heparin, warfarin, low molecular weight heparins (enoxaparin [Lovenox®], dalteparin [Fragmin®], tinzaparin [Innohep®]), fondaparinux (Arixtra®), and the direct thrombin inhibitors (DTI) lepirudin (Refludin®), argatroban® and bivalirudin (Angiomax®). The 2 most recently approved anticoagulants, desirudin (Iprivask®) and dabigatran (Pradaxa®), are discussed in detail with special emphasis on dabigatran – the first oral anticoagulant to reach the U.S. market in 50 years. Special concerns with dabigatran and the role of healthcare providers in educating and monitoring patients treated with the new drug are summarized. Dabigatran will likely be joined by other new oral anticoagulants within a few years. An introduction to the two most promising agents, rivaroxaban and apixaban, is also provided. In the Figure and Tables, you’ll find a quick comparison of the key features of both established and new anticoagulants.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 0428-0000-11-107-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.